Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan SALT LAKE CITY, April 14, 2026 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the use of the MyChoice® Test for prostate cancer patients as a companion diagnostic for Lynparza® (olaparib). With this approval, clinicians can now order the MyChoice Test to determine homologous recombination deficiency (HRD) status for patients with ovarian cancer, and BRCA1/2 statu...
Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting SALT LAKE CITY, April 09, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces that it will share new data at the Society of Gynecologic Oncology (SGO) Annual Meeting, including two oral presentations and two posters. “Having four abstracts accepted at the prestigious SGO annual meeting underscores the importance of the data we are sharing and our commitment to the cancer care continuum,” said Dale Muzzey, ...
A director at Rexford Industrial Realty Inc sold 23,132 shares at 35.291USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer Approval reinforces Myriad’s leadership in comprehensive HRD testing and establishes MyChoice CDx as the only FDA-approved companion diagnostic for Zejula in the United States SALT LAKE CITY, March 17, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the ® CDx Test as the Companion Diagnostic (CDx) for ® (ni...
AMREP Reports Third Quarter Fiscal 2026 Results HAVERTOWN, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- AMREP Corporation (NYSE:AXR) today reported net income of $3,147,000, or $0.58 per diluted share, for its 2026 fiscal third quarter ended January 31, 2026 compared to net income of $717,000, or $0.13 per diluted share, for the same period of the prior year. For the first nine months of 2026, AMREP had net income of $9,039,000, or $1.68 per diluted share, compared to net income of $8,823,000, or $1.64 per diluted share, for the same period of 2025. Revenues were $14,573,000 and $41,823,000 fo...
Myriad Commercially Launches Precise MRD with Select Community Oncologists Launch Represents Significant Step to Broader Commercialization SALT LAKE CITY, March 02, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces the launch of the ™ (molecular residual disease) test with a select number of oncology practices for patients with breast cancer. “The limited release of Precise MRD represents an important milestone in cancer care for patients and the clinicians who guide their care. By detecting ctDNA at extremely low...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.